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Which Clinical Diagnostic Tools are most Effective for the assessment of 
Women with the Menopause whilst Opioid Dependent? 
Abstract  
Opioid addiction and the Menopause have intrinsic signs and symptoms, often complicated 
by a misdiagnosis affecting the treatment options, which could otherwise prolong life. The 
Menopause is commonly diagnosed in middle aged women through blood testing and 
urinalysis. Equally, Opioid dependence is diagnosed through urinalysis, assessment and the 
use of diagnostic tools. An understanding of utilising Clinical assessment tools can help 
reduce a misdiagnosis and such interventions should encourage health professionals to have 
the confidence in effective decision making in clinical assessment.  
Keywords: Menopause, Opioid dependence, Hormone Replacement Therapy, Clinical 
Diagnostic tools 
Aims and Learning Outcomes 
The  Aim  of  this  article  is  to  help  develop  nurse’s  knowledge  and understanding on which 
clinical diagnostic tools are most effective in diagnosing women who are opioid dependent 
and experiencing the Menopause. It will help to  develop  nurse’s  knowledge  of Opioid 
dependence disorders, the inevitable effects of the menopause and how using clinical 
diagnostic tools can help reduce the detrimental effects of unwanted symptomatology. This 
article should enable health professionals to: 
 Identify appropriate clinical diagnostic tools for diagnosing the Menopause and 
Opioid Dependence. 
 Discuss factors that cause the onset of the Menopause in women and symptoms of 
Opioid Dependence that may interfere with a formal diagnosis. 
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 State how Opioid dependence and the Menopause can be assessed, detected and 
diagnosed effectively (to help distinguish these conditions). 
 Explain the principals of managing Menopause occurrence, Opioid dependence and 
symptomatology. 
 Discuss the implications of misdiagnosing the Menopause and Opioid dependence. 
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Introduction 
Opioid Dependence is a chronic relapsing disorder associated with misuse and low mortality 
rates worldwide (Hser et al, 2013). Opioid dependence resulted in 51,000 deaths in 2013, up 
from 18,000 deaths in 1990 (Global Burden of Disease Study, 2015).The descriptive 
characteristics of opioid dependence includes a strong desire to take opiates, difficulties in 
controlling the use of opiates and a physiological withdrawal state (Praveen et al, 2012). 
There is a concern that women are being misdiagnosed with opiate withdrawal symptoms 
whilst displaying menopausal symptoms. Equally, women being diagnosed with the 
Menopause whilst displaying Opiate withdrawal symptomatology (Clayton & Ninan, 2010).  
The conflicting diagnoses could be due to identified similarities in the symptomatology 
(Table 1). This could result in treatment options being inaccessible, which could otherwise 
prolong the quality of life for both conditions (Fehring et al, 2006). The implications for 
Opioid dependent women being misdiagnosed could result in severe Opiate withdrawals, 
seizures, physiological and mental health distress. Opiate withdrawal treatment consists of 
hospital inpatient, community and GP pharmacological treatment (NICE, 2015).  
Generally, the Menopause is an inevitable event affecting all middle-aged women and 
menopausal symptoms can differ in terms of severity and duration (Whitham, 2013). NICE 
guidance (2015) suggests that the women are more at risk of chronic disease after the 
Menopause. Chronic diseases may include osteoporosis, urogenital atrophy, cardiovascular 
disease and the risk of a stroke increases after the Menopause (British Menopause Society 
Council, 2011). Therefore, there is a need to accurately identify symptoms early, offer 
appropriate treatment and promote long-term health for women (Holloway, 2011).  
Diagnosing the Menopause is routinely assessed through blood and urine test results, self-
diagnosis and determining the final menstrual cycle, which is normally 12 consecutive 
4 
 
months following amenorrhea (Brockie, 2013). However, the measurement of efficacy in 
diagnosing the Menopause is limited. Clinical Diagnostic Tools could potentially minimise 
the risk of a possible misdiagnosis, identify chronic health risks presented and guide the 
primary care nurse to make a reliable, valid and coherent assessment (Whitham, 2013).  
Timeout 1: Medication: Opiate withdrawal symptoms can be severe and menopausal 
symptoms equally. What other Adjunctive therapies are appropriate for managing these 
symptoms? Check Drug Misuse and Dependence (NICE, 2007) & BNF 68 (2014): 
Oestrogens; female sex hormones for HRT.  
 
The Opiate Dependence Symptomatology 
Diagnosing Opioid dependence is established through urinalysis (Opiate metabolites in 
urine), history taking and examination (Praveen et al, 2012).Opioids are typically prescribed 
for people who have acute and chronic pain, cancerous and non- cancerous pain and Opioid 
addiction. Typically heroin, opium and or over the counter opioid medication is often 
misused (NICE, 2007).  
Some of the Symptoms of withdrawal from Opioids are similar to the onset of the Menopause 
such as the early symptoms, psychological and other symptomatology. Table 1 is adapted by 
Holloway (2011) & (Kheirabadi et al, 2008) . 
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Table  1:  Opiate  withdrawal  Symptoms  V’s  Menopausal  Symptoms 
Opiate Withdrawal Symptoms Menopausal Symptoms 
Early symptoms 
Sweating  
Night sweats 
Increased tearing 
 Insomnia 
Sleep Disturbances 
Shivering 
Increased Pulse 
 Runny nose 
 Yawning 
Skin-Crawling 
heart pounding; palpitations 
 Muscle aches and pains 
 Psychological Symptoms 
Agitation 
 Anxiety 
Mood Changes 
irritability  
Dysphoria. 
Late symptoms 
 Abdominal cramping 
Diarrhoea 
 Dilated pupils 
 Goose bumps 
 Nausea 
 Vomiting. 
(Kheirabadi et al, 2008) 
Vasomotor Symptoms 
Sweating 
Night Sweats 
Hot Flushes 
Insomnia 
Sleep Disturbances 
Shivering 
Increased Pulse 
Nausea 
Palpitations 
Vaginal and Urinary Symptoms 
Vaginal Infections 
Post-coital Bleeding 
Dysuria 
Psychological Symptoms 
Anxiety 
Mood Changes 
Irritability 
Decreased Libido 
Other Symptoms 
Skin Crawling 
Amenorrhoea 
Abdominal Cramps 
Aches and pains in muscles; joints. 
(Holloway, 2011) 
 
 
 
 
Arguably, Amenorrhea in women with Opioid dependence is a common condition. Opioid 
dependence symptomatology (Table 1) can also lead to a misdiagnosis of the early onset of 
the Menopause due to the presence of amenorrhoea (Reddy et al, 2010).  Pharmacological 
treatment is a primary intervention for Opioid dependence (Table 2). Sometimes Opiate 
withdrawal requires medications which are controlled under the Drug Misuse Act (1971) 
such as methadone and buprenorphine (Hser et al, 2013). Methadone is usually given as a 
“first  line  choice”  due  to  its  cost  effectiveness,  alternative dosing and reduction in injecting 
behaviour and buprenorphine can equally be prescribed. However, buprenorphine has partial 
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agonistic properties which make precipitated Opiate  withdrawal  more  prevalent  in  “first  time 
prescribing”  (NICE,  2015). 
 
 
Interventions for Opioid Addiction 
Induction onto Opioid Substitute Prescribing (OST) takes 2-4 weeks, with the risks of 
overdose and toxicity being prevalent (Mckeganey et al, 2013). Buprenorphine is effective in 
treating withdrawal from opiates, and it can shorten the length of detoxification. 
Buprenorphine can also be used for long-term maintenance, like Methadone (Praveen, 2012). 
Methadone is limited by side effects influencing compliance, resulting in inadequate 
treatment retention (Hser et al, 2013). Methadone induction involves slowly decreasing the 
dosage of over time, which helps reduce the intensity of opiate withdrawal symptoms (Beck 
et al, 2014). Other medications may be considered, such as anti-psychotics, anti-depressants 
and benzodiazepines for the management of an opioid detoxification (NICE, 2007). Table 2 
demonstrates an outline of the management process associated with Opioid dependence and 
the Menopause in the UK. 
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Table 2: Principals in managing Opioid addiction and the Menopause in the UK (NICE, 
2015) 
Interventions Opioid Treatment Menopausal Treatment 
Pharmacological  Methadone 
Buprenorphine 
Suboxone 
Benzodiazepine 
Lofexidine 
Paracetamol  
Hypnotic 
Anti- depressant 
medication 
Anti- Psychotic 
Anti Convulsant 
medication 
(BNF, 2014) 
Hormone Replacement 
Therapy (HRT) 
Tibolone 
Ethinylestradol 
Raloxifene 
Dydrogesterone 
Medroxyprogesterone 
acetate 
Norethisterone 
Progesterone 
Uliprisal acetate 
Clonidine. 
Vaginal lubricants. 
Antidepressants (BNF, 
2014) 
Use of 
Pharmacological 
Treatment 
Maintenance therapy for 
Opioid dependence  
Adjunctive therapy for 
opiate withdrawal 
&Psychiatric intervention. 
(Nice, 2015) 
Relief of menopausal 
symptomatology e.g. hot 
flushes. Psychiatric 
intervention (NICE, 2015). 
Psychosocial 
Interventions 
Cognitive Behavioural 
Therapy (CBT) 
Contingency Management 
Relapse prevention. 
Motivational Interviewing  
 Self- help 
Counselling 
Contingency Management 
(CM)(Perry et al, 2014) 
Motivational Interviewing  
Cognitive Behavioural 
Therapy (CBT) 
Self- help 
Counselling 
(Perry et al, 2014) 
Clinical Diagnostic 
Tools 
COWS 
SOWS 
OOWS 
SDS 
SWAN 
CV 
MVS 
MRS 
Treatment Options GP 
Counselling 
Primary/mental health 
care 
Needle exchange 
programmes 
Wound care clinics- 
ulcers/ pressure sores. 
Inpatient referrals for 
detoxification (Public 
Health England, 2014) 
GP 
Counselling 
Primary/mental health care 
(British  Menopause 
Society Council, 2011) 
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The nature of nursing Opioid Dependence requires a range of specialist therapies such as 
Psycho-social interventions (PSI). PSI secondary to pharmacological treatment supports 
people who are opioid dependent (Perry et al, 2014). Some interventions (Table 2) may 
include; Cognitive Behavioural Therapy (CBT) which is aimed at modifying cognitive 
processes and behaviour. Motivational Interviewing (MI) is a ‘directive service user-centred’ 
counselling therapy, developed to modify behaviour and ‘Contingency Management’  (CM)  is 
a technique that provides a system of ‘incentives’ or ‘reinforcement’ to encourage abstinence 
(Klimas et al, 2014). PSI’s  support Opioid dependent women to develop coping mechanisms, 
daily living skills and techniques to control or abstain from drug use (Butler et al, 2014). CBT 
and  ‘Self-help’ has also beneficial use for the stressful menopausal transition (Holloway, 
2011).  
 
BOX 1 
Hormone Replacement Therapy (HRT) is an effective treatment for reducing the severity 
for vasomotor, psychological and urogenital symptoms (Brockie, 2013). The risks and 
benefits of HRT need to be discussed prior to treatment as the menopausal symptoms may 
return immediately on non-adherence to the medication. (Panay et al, 2013). There are a 
number of potential risks of breast cancer, deep vein thrombosis, stroke and coronary heart 
disease. The side effects of HRT medication are progestogen related: abdominal cramps, 
acne, anxiety, bleeding problems, depression, headaches and mood changes. (Holloway, 
2011).  
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The Menopause Symptomatology  
Menopausal symptoms naturally occur in women exhibiting the signs of peri-menopausal 
symptoms  in  their  40’s,  although  this  can  occur  in  women  in  their  early  30’s  and  as  late  as  
their  50’s (Whitham et al, 2013). The average age is not precisely defined, however, an 
important factor within the onset of the menopause. The Menopausal age is determined by 
genetics, environmental factors, surgery, chemotherapy and radiotherapy (Panay et al, 2013).  
 The Menopause is defined as the cessation of menstruation for a period of one year and 
follicles in the ovaries become less responsive to Follicle Stimulating Hormone (FSH) which 
stimulates the follicles prior to ovulation, until it ceases. FSH, estradiol and luteinizing 
hormone (LH) blood tests are routinely the most common way of diagnosing of the 
menopause (Holloway, 2011). International studies on effectively diagnosing the menopause 
suggest that blood testing for FSH and Estradiol is of limited value in establishing peri-
menopause due to extreme monthly fluctuating levels (British Menopause Society Council, 
2011). The confirmation of peri-menopause relies on a medical history taking and symptoms 
identification The Peri-menopause is the transitional phase from pre-menopause into 
Menopause. During the Peri-menopause ‘vasomotor’ or ‘somatic’ symptoms result from 
hormonal changes (Kahwati et al, 2005). Symptoms relating to the Menopause depend on 
lifestyle factors, hormones, health, relationships, genetic, and work (Table 1).  Hormone 
Replacement Therapy (HRT) (Box 1) may be considered as an effective therapy in managing 
these unwanted symptoms. (Reddish, 2011). 
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TIME OUT 2:Examples on Establishing a correct Diagnosis 
Table 1 introduces some of the signs and symptoms associated with the Menopause and 
Opiate withdrawal syndrome. Think about a middle aged woman you have nursed. Give an 
example on how the menopause could be incorrectly diagnosed in the context of your 
practice or expertise? What other health conditions resemble menopausal symptoms? What 
is the source of your information? 
 
Diagnostic Tools for distinguishing the Menopause and Opioid Dependence 
Unfortunately, no gold standard Clinical Diagnostic Tool exists for identifying women 
experiencing peri-menopausal symptoms. The evidence for utilising Clinical Assessment 
Tools for diagnosing the Menopause is limited in the U.K (Whitham et al, 2013). However, 
research is robust for the diagnosis and accurate assessment of Opiate withdrawal (Tompkins 
et al, 2009). Primary care nurses should effectively utilise an evidenced- based approach 
towards diagnosing health conditions. In addition, the use of Clinical Diagnostic Tools will 
improve health, prolong life and lessen the burden of unwanted symptoms (Fehring et al, 
2006). Typically, General Practitioners (GP) diagnose early and late stages of the menopause. 
When the Menopause is detected, healthcare professionals rely on diagnosing the 
‘Menopause’ through self-assessment, observations and having an awareness of the 
symptomatology presented (NICE, 2015). It is generally accepted that Pre, Peri and Post-
menopause  significantly  impacts  women’s  health (Panay et al, 2013).  
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TIMEOUT 3: Differential Diagnosis 
Go online or use a standard textbook to check your knowledge on Differential diagnoses 
associated with the Menopause and Opiate withdrawal. What other conditions may be 
causing the symptoms? How can you ensure you determine a correct diagnosis? 
 
Risk assessment plays an important role in the diagnosis and the identification of the 
Menopause (Reddish, 2011). Risk assessments can complement the formulation of a 
Differential diagnosis which can include Amenorrhoea, Irregular bleeding, Hot flushes, 
Endocrine causes, Mental Health problems and Drug (Opiates) and Alcohol misuse. Some 
other causes may include: Urinary incontinence, mood changes, cognitive disturbances, loss 
of libido, skin changes and weight gain (Perez-Lopez et al, 2013). In the UK, the clinical 
diagnosis of the Menopause is under researched due to the challenges of assessment 
(Holloway, 2011).  Misclassifications in ‘diagnosing’  the  Menopause can be the result of the 
‘Menopause  transition’. The menopausal transition progresses inconsistently, as regular 
menstrual cycles can occur after periods of irregularity leading to the misclassification of 
menopausal diagnosis or classification (Brockie, 2013).  The Menopause symptomatology is 
similar to Opiate Withdrawal (Table 1) such as mood changes, cognitive disturbances, loss of 
libido and skin changes (Mckeganey et al, 2013). 
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BOX 2: Examination of injecting sites for Drug Injecting Users 
People who inject drugs are vulnerable to viral and bacterial infections. These infections 
can result in high levels of illness and in death (Public Health England, 2014). The 
examination of injection sites can provide a useful indication on the timing and duration of 
drug use. Recent injecting sites show red inflammation and bruising, whereas older 
injecting sites show a multi-coloured pigmentation in the skin (WHO, 2015). Common 
injecting sites include the cubital fossa, groin and neck site.  
 
The Clinical Opiate Withdrawal Scale (COWS) 
The accurate assessment of opiate withdrawal is important in managing Opioid dependent 
women in community and inpatient settings. There are various methods of assessment which 
have been developed to improve on the specificity for opiate withdrawal detection (Tompkins 
et al, 2009). The Clinical Opiate Withdrawal Scale (COWS) is an eleven item scale used for 
in the assessment of opiate withdrawal. COWS can be completed in a couple of minutes and 
can identify opiate withdrawal through serial measurements of vomiting, aches and pains and 
changes in mood. COWS integrate the monitoring of physical vital signs; pupil dilation, 
pulse, blood pressure and temperature changes (Wesson & Ling, 2003).   
Alcohol Dependence can impair the diagnosis of Opioid Dependence due to similar 
withdrawal symptomatology and it may be important to consider completing clinical 
diagnostic tools such as the Severity of Alcohol Dependence Questionnaire (SADQ-C; 
Stockwell et al., 1983, 1994) and the Alcohol Use Disorders Identification Test (AUDIT)  
which is a Primary Care intervention to establish alcohol dependence (Henrique-Gonzalez & 
Patton, 2013).  
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Opioid dependency depends on the type and severity of Opiate withdrawals to make an 
accurate clinical assessment (Beck et al, 2013). The comprehensive assessment must 
determine a current history, social, forensic, past and present medical history. There is a 
requirement for opiate positive readings in drug urinalysis testing for a formal diagnosis and 
prescribing medication (NICE, 2015). Opioid detoxification relies on clinical assessment 
tools such as the COWS for monitoring symptoms associated with Opiate withdrawal. 
(Wesson & Ling, 2003). Health Complications of opioid dependence include: overdoses, 
death, blood Bourne viruses such as HIV, Hepatitis B and C (Box 2). The more serious the 
Opioid dependence is, the greater need for harm minimisation advice on safer sex, needle 
exchange and immunization (WHO, 2015) 
 
Subjective Opiates Withdrawal Scale (SOWS) and the Objective Opiate 
Withdrawal Scale (OOWS) 
The Subjective Opiate Withdrawal Scale (SOWS) is designed to detect the severity of opiate 
withdrawal Symptoms (Kheirabadi et al, 2008). SOWS provide patients with an opportunity 
to be involved in there care, and assess their own symptoms of Opiate withdrawal (Table 1).  
This scale contains 16 symptoms of intensity the patient rates on a scale of 0 (not at all) to 4 
(extremely), and has been shown to be a valid and reliable indicator of the severity of the 
Opiate withdrawal. Symptoms  include  “I feel  anxious”  and  “my  muscles  twitch” which can 
help  reduce  the  “anxiety”  (Table 1) of Opiate withdrawal (Handlesman et al, 1987). SOWS 
has proven to be a highly valid and reliable indicator for a wide range of Opiate withdrawal 
symptoms (Kheirabadi et al, 2008).The Objective Opiate Withdrawal Scale (OOWS) 
provides  an  “objective  measure”  of  the  SOWS  and contains 13 physically observable signs, 
rated present or absent, based on a timed period of observation of the patient. The nurse 
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normally observes the patient during a 5 minute observation period then indicates a score for 
each of the opiate withdrawal signs in items 1-13 and then a total score (Handlesman et al, 
1987). Symptoms  include  “yawning”  “vomiting”  and  “hot  and  cold  flushes” (Table 1). 
SOWS and OOWS may be used as part of initial assessment and monitoring opioid 
withdrawal using Buprenorphine (Ford et al, 2013). 
 
 
 
Table 3: Severity of Dependence Questionnaire (adapted from Gossop et al, 1995) 
During the past year: 
 
(1) Did you think your use of [named drug] was out of control? 
(2) Did the prospect of missing a fix (or dose) or not chasing make you anxious or worried? 
(3) Did you worry about your use of [named drug]? 
(4) Did you wish you could stop? 
(5) How difficult did you find it to stop, or go without [named drug]? 
 
For questions 1–4 each item is scored on a four-point scale:  
0 never/almost never 
1 sometimes  
2 often 
3 always/nearly always 
 
Question 5 is also scored on a four-point scale, but here:  
0 not difficult 
1 quite difficult 
2 very difficult 
3 impossible 
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Severity of Dependence Scale (SDS) 
The Severity of Dependence Scale (SDS) is a diagnostic tool which takes a minute of a 
nurse’s  time.  SDS  is  a  5-item questionnaire that shows a score on the severity of dependence 
of Opioids. Each of the five items is scored on a 4-point scale (0-3). The total score is 
obtained through the addition of the 5-item ratings (Table 3). The SDS indicates the higher 
the score, the higher the level of dependence (Gossop et al, 1995). Diagnostic tools are highly 
important in establishing a formal diagnosis which in turn improves public health, well- being 
and recovery (The Drug Strategy, 2013).  
 
 
TIMEOUT 4: Opioid Diagnostic Tools Summary 
Look at the SDS questionnaire in table 2. What does it tell you about the assessment of 
opiate withdrawal? Do you feel this is an adequate tool for diagnosing opioid 
dependence? Several clinical assessment tools have been explored including: COWS, 
SOWS and OOWS.  
 
 
The Study  of  Women’s  Health Method (SWAN) 
Traditionally, the diagnosis of the Pre-menopausal symptoms is assessed through several 
methods of identification.  Predictive models for the Menopause focus primarily on 
classifying peri-menopause status including age, smoking status, vasomotor symptoms and 
cycle irregularities as predictors (Whitham et al, 2013). The  Study  of  Women’s  Health  across 
the Nation (SWAN) is a multi-ethnic, longitudinal, cohort study of US women (Santoro, 
2011). The SWAN method creates three classifications of the Menopause: 
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 Pre-menopausal- (Had a Cycle in the past three months and no changes in cycle 
length)  
 Early- menopausal- (Had a cycle in the past three months and changes in the cycle 
length)  
  Late menopausal; (Had a period in the past 12 months but not within 3 months). 
The SWAN shows positive results for accurate diagnosis (Torrens, 2009).  SWAN has 
associated certain patterns of hormones and symptoms with the metabolic status of a woman 
in menopausal state.  The relationship between hormones, body size, ethnicity, metabolic 
status and cardiovascular disease symptoms risks can vary as women traverse the Menopause 
and ovarian hormone production eventually ceases (Santoro, 2011). The SWAN 
Classification method in relation to diagnosis of the Menopause clearly outlines the 
distinction between early and late Menopause (Whitham et al, 2013). 
The Cervantes Scale (CS) 
In the UK and other developed countries several specific tools have been designed to identify 
and assess the Menopause  and  “quality  of  life” (Holloway, 2011). The purpose of the 31- 
item  “Cervantes  Scale”  (CS) is to assess menopausal symptoms in middle aged women 
experiencing premenopausal and late postmenopausal phases (Monterrosa- Castro et al, 
2012). This diagnostic assessment tool was developed following qualitative analysis of 
questionnaires in Spain relating to menopausal symptoms. The menopausal symptoms 
assessed included: Hot flushes, heart palpitations, muscle aches, anxiety and vaginal 
discomfort (Perez- Lopez et al, 2013). It was identified that in clinical practice over the past 
ten years, the 31 item CS tool was time-consuming. This CS diagnostic tool  was  “re-
developed”  and  “re-designed”  into  a  10  item  assessment  tool to ensure timely effective 
diagnosis in clinical settings. However, following recent research, the original 31- item was 
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deemed more valuable for the assessment of ‘female Menopause related quality of 
life’(Brockie, 2013). In contrary, this newly developed 10 item tool, created from the original 
CS, and is deemed more appropriate for a clinical assessment considering the pressures of 
staffing in primary care settings (Monterrosa- Castro et al, 2012). 
 
 
The Menopausal Vasomotor Symptoms Survey (MVS) & Menopause Rating 
Scale (MRS) 
Hot flushes combined with night sweats are common features of hormonal changes 
associated with the Menopause. The diagnosis of hot flushes can yet be inaccurate in some 
cases due to dietary and diversity lifestyles (Brockie, 2013). The Menopausal Vasomotor 
Symptoms Survey (MVS) for Assessment of Hot Flashes is a menopause diagnostic 
instrument  which  has  shown  a  more  rigorous  assessment  of  “hot  flushes”  than  the  Menopause 
Rating Scale (MRS), which is an 11- item scale for identifying menopausal symptoms (Ratka 
et al, 2006). MVS is a diagnostic tool created as there can be inaccuracies in clinical practice 
on  how  “hot  flushes”  are  understood and evidence suggests they are not well researched. 
MVS is a valid and reliable test consisting of 39 questions relating to differential dimensions 
of hot flushes and other health conditions (Table 2). The MVS is a structured questionnaire 
with a nominal measurement (yes or no answers) and an effective component in establishing 
“hot  flushes” (Ratka et al, 2006).  However, this diagnostic tool neglects numerous symptoms 
for diagnosing the menopause (Table 1).  
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Timeout 5. Nursing Implications for a misdiagnosis of a health condition. 
Have you been faced with a health condition that a diagnosis was uncertain? Have you 
seen your health colleagues debate a complicated condition? Do you rely on the 
consultant?  What are the likely implications of making a misdiagnosis? How can we best 
risk assess and protect the safety of our patients?  
 
Implications for the Health Professionals for Misdiagnosing the Menopause and 
Opioid dependence. 
There are a number of clinical concerns in misdiagnosing Opiate Withdrawal Syndrome with 
the Menopause. Symptoms associated with misdiagnosing the menopause with opiate 
withdrawal are similar (Table 1). Risks for a misdiagnosis include poor mortality, poor 
quality of life, physical health complications and chronic disease (Holloway, 2011). A 
misdiagnosis can impact the service delivery of care, nursing clinical workload, time and 
knowledge (Clayton & Ninan, 2010). This may lead to malpractice or clinical negligence. In 
addition, the public health bodies in the UK also play a major role drawing up and 
implementing guidelines to help prevent chronic disease (Brockie, 2013). The NMC (2015) 
has drawn up standards for managing clinical negligence. The standards ensure that the 
patient and public safety is protected and  a  duty  of  ‘candour’  is  upheld. Service providers 
need to provide nurses with regular up-dates on assessment, risk management and ensure 
appropriate Clinical Diagnostic Tools are utilised. This ensures a misdiagnosis is avoided and 
the management of relevant health conditions are appropriately managed (Clayton & Ninan, 
2010).  
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Conclusion 
In the UK and other developed countries Clinical Diagnostic Tools are used for a 
comprehensive assessment, risk assessment and monitoring ill health. However, the use of 
diagnostic tools for the assessment of the Menopause is limited. Assessment of Opiate 
withdrawal is primarily assessed with urinalysis and Clinical Diagnostic tools. Misdiagnosing 
natural  conditions  such  as  the  “Menopause”  can  have  an  impact  on  the  quality  of  life.  The  
misdiagnosis of “Opiate withdrawal” can equally cause harm, both physically and 
psychologically. In conclusion, Opiate withdrawal and the onset of the Menopause have 
shown similar symptoms and a misdiagnosis is best avoided with use of an appropriate 
Clinical Diagnostic Tool. 
 
 
TIMEOUT 6 Practice profile 
Now that you have completed the article, you might want to write a practice profile 
between 750- 1,000 words. Go to primary health care website: www.primaryhealthcare.net 
and follow the link to the learning zone for information on how to make a submission. 
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